small lot selling, mm,s showing big spread on bid/ask. minutes later buying at the bid to lift it right back up.
mm's whipsawing themselves in and out taking advantage of the large spreads, sounds like to me.
Not much volume still so suspect they are just trading small lots. should be a law against it IMO.
good luck All
ps; keep in mind the 50M shares was pre-split.
also, don't know the breakdown of the $16M on an individual basis......good luck All
According to the terms of an asset purchase agreement jointly executed by the parties, RXi will acquire substantially all of OPKO's RNAi-related assets, including an extensive intellectual property portfolio. The patent portfolio includes 12 patent families with claims relating to important biological targets, including vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1-alpha (HIF-1-alpha), intracellular adhesion molecule 1 (ICAM-1), angiopoietin 2 (Ang2), and complement component 3 (C3). These molecules are believed to play an important role in diseases of the eye, cancer, immune disorders, and inflammatory diseases. The acquisition is expected to close on March 12, 2013, subject to satisfaction of closing conditions.
As consideration for these assets, RXi will issue to OPKO 50 million shares of its common stock and will make milestone payments to OPKO up to an aggregate of $50 million per product tied to the successful development and commercialization of products utilizing the acquired OPKO intellectual property. In addition, upon commercialization of these products, if approved, RXi would make royalty payments to OPKO.
hanna, around March 2013 a private placement $16+ million led by opko health and Frost gamma invstm trust.
a solid though hanna, One should never underestimate the human element. After all these folks are not in it for the exercise.
On the other hand why would Frost make the investment, meaning the asset transfer along witha private placement of $ 16 million?. This would not add to your equation IMHO.
I t seems to me that Frost and Opko may possibly stand more to gain on RXI's success based on the their stockposition than they would a buyout.
It does certainly appear that there are forces keeping the price down......good luck All
was a no risk for Dr. Frost. Can they explain why, at about the same time, Dr. Frost along with 15 or so additional investors make a private placement of over $16 million (non dilutional) to RXI in addition to the asset transfer?
gentlemen the half truths just do not cut it. Fear tactics based on distorted information is the best they can do. What is puzzling is why they hang around this board doing it........
Autumn's previous post is right on...................good luck All
good post martina, just to add;
WESTBOROUGH, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the Company’s Board of Directors. Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
“Dr. Lockshin has an impressive career track record in research and development of new drugs”
Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University. “Mr. Dorman is one of the remarkable icons in the healthcare industry and we are thrilled to have him join our Board,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, “Paul’s experience and network in both the large and small pharma world, as well as his wisdom in leading companies to success, will be major contributing factors to the RXi Board of Directors and the growth of our Company.”
Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. Most recently, he has been an Independent Pharmaceutical & Life Sciences Consultant for OPKO Health, Inc. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO's R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. “Dr. Lockshin has an impressive career track record in research and development of new drugs”, commented Dr. Geert Cauwenbergh. “With RXi Pharmaceuticals in the midst of a game changing drug in development with RXI-109 for dermal scarring, Curt will provide valuable insights into the development of our drugs. With Paul Dorman and Curt Lockshin joining our current Board members Bob Bitterman and Keith Brownlie, RXi Pharmaceuticals has a well rounded Board of Directors with an appropriate balance of all key elements needed for success.”
hedge, for someone who touts his millions, it puzzles me why you hang around the message board of a small developmental biotech.
My personal feeling is that you would not be hanging around here just for the company.
and yes, I agree, hanna has a very good take on things IMO.
You did state earlier that your reasons for being here were to enact some revenge on red,....
says a lot of an individual ...... I expect that you may be in dire need of a personality hedge.........................................
certainly is unusual activity, at times today a 20 cent spread.
I suspect many waiting on cohort results due in November along with start of Ph2. at the present time there seems no urgency to buy.
I am also long. Nothing has changed, as far as I can tell and according to Cauwenbergh all is progressing as planned. I have not seen or heard anything to make me think otherwise.
Some positive news is needed to jump start this stock and as we have all seen it does not take much activity to make it move IMHO..........good luck All
to warn us of he pitfalls of investing in RXI. why? because he is such a magnanimous human being who is only interested in our well being. what a guy.
Never a thought of himself. where do you find people like that.........................
No hedge, I do not refuse to like your message, I refuse to think that you go out of your way to the extent that you have to warn us of lesser knowledge about the pitfalls of this company.
Your tactics are to scare investors in RXI wih market factors, fine if you discount the potential of the company, of its science and progress yo have yet to address.
why you regret to address the solid progress of the company is what puzzles me.
You short companies for a living, that's fine, but you should at least give an honest assessment of the whole picture.
You cannot do that, why? because your motive is to attempt to scare investors with market factors, of which you seem to have a semblance of expertise, but on the whole, you are a one dimentional fear monger without the slightest knowledge of the company or its promise.
In a word hedge, you're agenda is exposed, and in my opinion, you're message does not cut it here.
Your messages "for free" are not worth the price.........
Just another jerk basher who thinks he has the lingo to make people listen................................................
incorrect grammar donh, one (must) correct his spelling.
as opposed to "need to clarify your spelling". How does one clarify spelling?
You should work on you're grammar.............
how do you like being corrected for a simple error?
Exactly so hanna. Mr hedge just up to his old scare tactics.
There is no doubt as to his motives. he's so scary isn't he ?
not a lot at one time, but steady buying nonetheless...
excerpt from "3 reasons to buy RXI"
RXi Pharmceuticals has taken a completely different approach that involves building drug-like properties into the RNAi compound itself. The result is a therapy that combines the preferable delivery of antisense technology and the intracellular potency of RNAi compounds, with high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake for a wide variety of different RNAi therapeutic targets.
The resulting sd-rxRNA® platform has consistently demonstrated its efficient and universal cellular uptake in bothin vitro and in vivo studies, including those focused on the skin, retina, lung, spinal cord and liver. With this unique and unprecedented ability, the patented platform could potentially unlock the vast potential of RNAi therapeutics for local treatments in skin, oral, eye, ear, anorectic, arthroscopy and endoscopy procedures in the U.S. and abroad.
a good day to All
no paid bashers. been a follower of this co. over two hears, not a trader but been been in and out three times or more.
Just cannot see any promise left in this one. If you can give some thoughtful reasoning why you feel this company is still a good investment I'd love to hear it.
too many companies with much more promise out there, I wouldn't beat this dead horse, even with play money.............good luck to you
even made a small profit. am now convinced that this is not a viable company.
Whatever shot they had at getting off the ground is now long past.
Just a few pumping traders slinging the usual hype..........good luck All
quite so hanna, but even with the preferreds converted still a very low mkt cap IMO.
Take a look at ALNY with an admittedly expanded pipeline vs: RXI. None of which has nearly the mkt potential of rx-109, also no drugs on market;
yet their market cap is nearly $4 billion. Any rhyme or reason to it?
If and when RXI gets a few more candidates into the clinical we could see their MC increase exponentially.
good post hanna......................good luck All.
not in entirety autumn, most of it is Greek to me, but will revisit tomorrow. many thanks for sending....................